clinical trial · NCT05006716
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
BeOne Medicines·phase2·recruiting·n = 645
B-cell MalignancyMarginal Zone LymphomaFollicular LymphomaNon-Hodgkin LymphomaWaldenström MacroglobulinemiaChronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaMantle Cell LymphomaBGB-16673
brief summary
Study consists of two main parts to explore BGB-16673 recommended dosing, a Phase 1 monotherapy dose finding comprised of monotherapy dose escalation and monotherapy safety expansion of selected doses, and a Phase 2 (expansion cohorts)
started
Sep 13, 2021
primary completion
Nov 1, 2026
completion
Nov 1, 2029
last updated
Jun 18, 2026
detailed description
Our company, previously known as BeiGene, is now officially BeOne Medicines. Because some of our older studies were sponsored under the name BeiGene, you may see both names used for this study on this website.
official title
A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol